haloprogin - Profile

What are the generic drug sources for haloprogin and what is the scope of patent protection?

Haloprogin is the generic ingredient in one branded drug marketed by Westwood Squibb and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

Summary for haloprogin

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for haloprogin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Westwood Squibb	HALOTEX	haloprogin	CREAM;TOPICAL	016942-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Westwood Squibb	HALOTEX	haloprogin	SOLUTION;TOPICAL	016943-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Investment Scenario and Fundamentals Analysis for Haloprogin

Last updated: February 20, 2026

What is Haloprogin?

Haloprogin is an antifungal agent originally developed to treat skin infections such as tinea corporis and tinea pedis. It was introduced in the 1960s but eventually phased out from the market due to limited efficacy and safety concerns. Currently, it is not marketed, and no active pharmaceutical ingredient (API) sales or commercial products are available.

Market and Regulatory Status

Aspect	Details
Approval Status	Approved in the US (1970s-1980s); withdrawn from U.S. market circa 1985
Current Market Presence	Absent; no marketed formulations or authorized generic competitors
Regulatory Pathways	No recent regulatory filings or approvals; potential for re-evaluation
Patent Landscape	No active patents; original patents expired decades ago

Pharmacological Profile and Fundamentals

• Mechanism of Action: Disrupts fungal cell membrane synthesis by interfering with sterol production.
• Spectrum of Activity: Effective against dermatophytes; limited data on yeast or mold fungi.
• Toxicity Profile: Reports of skin irritation; safety concerns from outdated trials.
• Formulation: Topical cream, ointment; no current formulations available.

Commercial and Competitive Landscape

• Existing Drugs: Terbinafine, clotrimazole, miconazole dominate the topical antifungal market.
• Market Revenue: Estimated global antifungal market in 2022 was approximately USD 11 billion; OTC segments constitute the majority.
• Market Entry Barriers:
  • No current patent protection.
  • Outdated safety and efficacy data.
  • Established competition with superior safety profiles.

Investment Considerations

Factor	Analysis
Market Potential	Low for reintroduction; saturated with well-established molecules and OTC options
Development Costs	High, including reformulation, preclinical testing, safety, and efficacy studies
Regulatory Challenges	Significant; need for new clinical trials and safety data to regain approval
Patent and IP Landscape	No active patents; potential for new formulation patents but limited exclusivity
Commercial Viability	Questionable; likelihood of rapid obsolescence given existing competition

Risks and Challenges

• Efficacy and Safety: Sufficiently outdated; requires comprehensive re-evaluation.
• Regulatory Approval: Uncertain; might necessitate phase I/II trials.
• Market Acceptance: Limited, given strong existing medications and OTC options.
• Manufacturing: Need for modern formulation development and stability testing.

Opportunities

• Niche Repositioning: Could develop for resistant fungal strains if demonstrated to be superior.
• Patent Opportunities: Novel formulations or drug delivery systems.
• Combination Therapy: Potential synergy with other antifungals.

Summary

Investing in re-developing haloprogin presents high scientific and regulatory risks with limited potential for competitive advantage. The existing market is saturated with better-tolerated, well-studied antifungals, reducing the likelihood of commercial success. Strategic focus should shift toward developing novel antifungal agents or repositioning drugs with current patent protection and better safety profiles.

Key Takeaways

• No current market or regulatory pathway exists for haloprogin in its original form.
• The antifungal market is highly competitive, dominated by molecules with proven safety and efficacy.
• Significant investment would be required to develop safety data, formulations, and obtain regulatory approval.
• The absence of patent protection limits exclusivity potential.
• Market entry risks outweigh potential benefits, barring innovative repositioning or combination strategies.

FAQs

1. Can haloprogin be repurposed for resistant fungal strains?
   Current data do not support efficacy against resistant strains; extensive research and trials are necessary.

2. Are there ongoing clinical trials involving haloprogin?
   No recent initiatives or clinical trials are publicly documented.

3. What regulatory hurdles exist for reintroducing haloprogin?
   Reintroduction would require new safety and efficacy data, including phase I/II trials and regulatory review.

4. What are competitors' advantages over haloprogin?
   Better safety profiles, existing formulations, and widespread OTC availability.

5. Could patenting new formulations revive haloprogin?
   Only if novel delivery systems or formulations meet patent criteria; otherwise, limited market exclusivity.

---

References

[1] U.S. Food and Drug Administration. (1985). History of antifungal agents. Retrieved from https://www.fda.gov.
[2] MarketWatch. (2022). Global antifungal market overview.
[3] PatentScope. (2023). Patent landscape for topical antifungal agents.